Advanced HER2+ disease in the era of adjuvant Herceptin

[Debbie L.]

I'm not sure I can clearly explain my question. Maybe Lani can help with both question and answer?

I suspect that there is a big difference in outcome for those who recurred after primary treatment that did not include Herceptin (or any anti-HER2 agent) and those who got Herceptin adjuvantly. Specifically, I wonder if any of the longterm NED survivors of stage IV HER2+ disease (the ones who might well be cured) includes any of those who recurred after receiving adjuvant Herceptin?

Does anyone know of any studies or discussions that have looked at this?

Let me know if my question is not making sense to you and I'll try to clarify.

Debbie L.